This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these template messages) This article needs to be updated. Please help update this article to reflect recent events or newly available information. (November 2021) This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed.Find sources: "TA-NIC" – news · newspapers · books · scholar · JSTOR (February 2023) (Learn how and when to remove this message) (Learn how and when to remove this message)

TA-NIC is a proprietary vaccine in development similar to TA-CD but being used to create human anti-nicotine antibodies in a person to destroy nicotine in the human body so that it is no longer effective.[1]

TA-NIC is a vaccine in development as an aid to quitting smoking in motivated patients. TA-NIC is an immunotherapeutic vaccine similar in concept to TA-CD, designed to raise anti-nicotine antibodies. The antibodies bind to nicotine molecules in the patient's blood stream, reducing the rate and quantity of nicotine entry into the brain and thus reducing the positive reinforcement and addiction associated with nicotine and cigarette smoking. It is expected that the reduction of the positive reinforcement will in turn reduce the desire to smoke or use other tobacco products. Treatment with TA-NIC is expected to be part of a comprehensive smoking cessation management program that includes other supportive measures.

Results from its clinical trials are not publicly available, although one of its developers, Thomas Kosten, disclosed in an email that the vaccine was not found to be effective enough to continue development.[2]

Notes

  1. ^ "CelticPharma: TA-NIC Nicotine Dependence". Archived from the original on 2009-12-06. Retrieved 2009-10-27.
  2. ^ Truong, Thanh Thuy; Kosten, Thomas R. (15 March 2022). "Current status of vaccines for substance use disorders: A brief review of human studies". Journal of the Neurological Sciences. 434: 120098. doi:10.1016/j.jns.2021.120098. ISSN 0022-510X.
Categories